Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 17/20 | 0.67 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.56 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.56 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7205056 | 0.88 | PRKDC (0.56) | PRKDCPIK3CDPIK3CAPIK3CBKCNH2 | |
| SCHEMBL16235102 | 0.83 | PRKDC (0.50) | PRKDCPIK3CDPIK3CAPIK3CBKCNH2 | |
| SCHEMBL17804470 | 0.82 | PRKDC (0.67) | PRKDCPIK3CDPIK3CAPIK3CBKCNH2 | |
| SCHEMBL28511289 | 0.82 | PRKDC (0.67) | PRKDCPIK3CDPIK3CAPIK3CBKCNH2 | |
| SCHEMBL28490013 | 0.80 | PRKDC (0.45) | PRKDCPIK3CDPIK3CAPIK3CBKCNH2 | |
| SCHEMBL19248288 | 0.80 | PRKDC (0.44) | PRKDCPIK3CDPIK3CAPIK3CBKCNH2 | |
| SCHEMBL12324936 | 0.80 | PRKDC (1.00) | PRKDC | |
| SCHEMBL31302329 | 0.79 | PRKDC (0.52) | PRKDCPIK3CDPIK3CAPIK3CBKCNH2 | |
| SCHEMBL2421027 | 0.79 | PRKDC (0.52) | PRKDCPIK3CDPIK3CAPIK3CBKCNH2 | |
| SCHEMBL16256180 | 0.79 | PRKDC (0.62) | PRKDCPIK3CDPIK3CAPIK3CBKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240366614-A1 | ARYLQUINAZOLINES | MERCK PATENT GMBH (DE) | 2024-11-07 | — | — | US | disclosed |
| US-20220117970-A1 | ARYLQUINAZOLINES | MERCK PATENT GMBH (DE) | 2022-04-21 | — | — | US | disclosed |
| US-20220117970-A1 | ARYLQUINAZOLINES | MERCK PATENT GMBH (DE) | 2022-04-21 | — | — | US | disclosed |
| US-11065253-B2 | Arylquinazolines | MERCK PATENT GMBH (DE) | 2021-07-20 | — | — | US | disclosed |
| US-11065253-B2 | Arylquinazolines | MERCK PATENT GMBH (DE) | 2021-07-20 | — | — | US | disclosed |
| CN-112300132-A | Aryl quinazoline DNA-PK inhibitor | 山东轩竹医药科技有限公司 | 2021-02-02 | — | — | CN | disclosed |
| US-20200069690-A1 | ARYLQUINAZOLINES | MERCK PATENT GMBH (DE) | 2020-03-05 | — | — | US | disclosed |
| US-20200069690-A1 | ARYLQUINAZOLINES | MERCK PATENT GMBH (DE) | 2020-03-05 | — | — | US | disclosed |
| US-10383874-B2 | Arylquinazolines | MERK PATENT GMBH (DE) | 2019-08-20 | — | — | US | disclosed |
| US-10383874-B2 | Arylquinazolines | MERK PATENT GMBH (DE) | 2019-08-20 | — | — | US | disclosed |
| US-9126952-B2 | Morpholinylquinazolines | MERCK PATENT GMBH (DE) | 2015-09-08 | — | — | US | disclosed |
| US-9126952-B2 | Morpholinylquinazolines | MERCK PATENT GMBH (DE) | 2015-09-08 | — | — | US | disclosed |
| US-9126952-B2 | Morpholinylquinazolines | MERCK PATENT GMBH (DE) | 2015-09-08 | — | — | US | disclosed |
| WO-2014183850-A1 | ARYLQUINAZOLINES | MERCK PATENT GMBH (DE) | 2014-11-20 | — | — | WO | disclosed |
| EP-2547664-A1 | MORPHOLINYLQUINAZOLINES | Merck Patent GmbH (DE) | 2013-01-23 | — | — | EP | disclosed |
| US-20130012489-A1 | Morpholinylquinazolines | MERCK PATENT GMBH (DE) | 2013-01-10 | — | — | US | disclosed |
| US-20130012489-A1 | Morpholinylquinazolines | MERCK PATENT GMBH (DE) | 2013-01-10 | — | — | US | disclosed |
| US-20130012489-A1 | Morpholinylquinazolines | MERCK PATENT GMBH (DE) | 2013-01-10 | — | — | US | disclosed |
| WO-2011113512-A1 | MORPHOLINYLQUINAZOLINES | MERCK PATENT GMBH (DE) | 2011-09-22 | — | — | WO | disclosed |
| WO-2011113512-A1 | MORPHOLINYLQUINAZOLINES | MERCK PATENT GMBH (DE) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012489-A1 | Morpholinylquinazolines | LATS2, TNK2, SKP1 | PRKDC 2343/4885PIK3CD 1763/4885PIK3CA 643/4885 |
| US-20240366614-A1 | ARYLQUINAZOLINES | CHEK2, CHEK1, MAP3K19 | PRKDC 205/4885PIK3CD 631/4885PIK3CA 421/4885 |
| US-20220117970-A1 | ARYLQUINAZOLINES | CHEK2, CHEK1, MAP3K19 | PRKDC 205/4885PIK3CD 631/4885PIK3CA 421/4885 |
| US-10383874-B2 | Arylquinazolines | CHEK2, CHEK1, ATM | PRKDC 262/4885PIK3CD 711/4885PIK3CA 509/4885 |
| US-11065253-B2 | Arylquinazolines | CHEK2, CHEK1, MAP3K19 | PRKDC 205/4885PIK3CD 631/4885PIK3CA 421/4885 |
| US-20200069690-A1 | ARYLQUINAZOLINES | CHEK2, CHEK1, MAP3K19 | PRKDC 205/4885PIK3CD 631/4885PIK3CA 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.